following a full submission
enzalutamide (Xtandi®) is accepted for use within NHS Scotland.
Indication under review: Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.
In one randomised, double-blind, phase III clinical study, enzalutamide significantly increased overall survival compared with placebo.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of enzalutamide. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
|Drug Name:||enzalutamide (Xtandi)|
|SMC Drug ID:||911/13|
|Manufacturer:||Astellas Pharma Ltd|
|Indication:||Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.|
|Submission Type:||Full submission|
|Date Advice Published:||11 November 2013|